Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Vicore Pharma Holding AB (publ) before investing.

In this article, we go over a few key elements for understanding Vicore Pharma Holding AB (publ)’s stock price such as:

• Vicore Pharma Holding AB (publ)’s current stock price and volume
• Why Vicore Pharma Holding AB (publ)’s stock price changed recently
• Upgrades and downgrades for VCRE from analysts
• VCRE’s stock price momentum as measured by its relative strength

About Vicore Pharma Holding AB (publ) (VCRE)

Before we jump into Vicore Pharma Holding AB (publ)’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis. It has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.

Want to learn more about Vicore Pharma Holding AB (publ)’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Vicore Pharma Holding AB (publ).

Vicore Pharma Holding AB (publ)’s Stock Price as of Market Close

As of September 04, 2026, 3:59 PM, CST, Vicore Pharma Holding AB (publ)’s stock price was $11.590.

Vicore Pharma Holding AB (publ) is up 0.35% from its previous closing price of $11.550.

During the last market session, Vicore Pharma Holding AB (publ)’s stock traded between $11.100 and $11.650. Currently, there are approximately 29.05 million shares outstanding for Vicore Pharma Holding AB (publ).

Vicore Pharma Holding AB (publ)’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Vicore Pharma Holding AB (publ) Stock Price History

Vicore Pharma Holding AB (publ)’s (VCRE) price is currently up 4.98% so far this month.

During the month of September, Vicore Pharma Holding AB (publ)’s stock price has reached a high of $11.650 and a low of $10.470.

Over the last year, Vicore Pharma Holding AB (publ) has hit prices as high as $17.800 and as low as $10.470.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Vicore Pharma Holding AB (publ) Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 04, 2026, there were analysts who downgraded Vicore Pharma Holding AB (publ)’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Vicore Pharma Holding AB (publ)’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Vicore Pharma Holding AB (publ)’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Vicore Pharma Holding AB (publ)’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Vicore Pharma Holding AB (publ) (VCRE) by visiting AAII Stock Evaluator.

Relative Price Strength of Vicore Pharma Holding AB (publ)

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 04, 2026, Vicore Pharma Holding AB (publ) has a weighted four-quarter relative price strength of %, which translates to a Momentum Score of and is considered to be NA.

Want to learn more about how Vicore Pharma Holding AB (publ) is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Vicore Pharma Holding AB (publ) Stock Price: Bottom Line

As of September 4, 2026, Vicore Pharma Holding AB (publ)’s stock price is $11.590, which is up 0.35% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Vicore Pharma Holding AB (publ) stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.